Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APM NASDAQ:CRDL TSE:CXF NASDAQ:IPA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPMAptorum Group$1.37-11.6%$1.18$0.46▼$7.49$8.29M-0.1110.24 million shs127,954 shsCRDLCardiol Therapeutics$1.38-7.4%$1.36$0.77▼$2.63$123.18M1.05367,737 shs795,076 shsCXFCI Canadian Convertible Bond ETF CommonC$10.36-0.4%C$10.23C$9.72▼C$10.57C$52.37MN/A4,257 shs300 shsIPAImmunoPrecise Antibodies$1.64-1.2%$1.22$0.27▼$2.41$76.62M0.492.14 million shs1.01 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPMAptorum Group-11.61%-24.31%+48.27%+47.31%-58.48%CRDLCardiol Therapeutics-7.38%-4.17%-0.72%+21.05%-36.11%CXFCI Canadian Convertible Bond ETF Common-0.38%+1.07%+1.97%+4.65%+3.50%IPAImmunoPrecise Antibodies-1.20%-24.07%+54.72%+257.22%+107.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPMAptorum Group1.023 of 5 stars0.05.00.00.00.61.70.6CRDLCardiol Therapeutics1.9453 of 5 stars3.74.00.00.00.00.00.6CXFCI Canadian Convertible Bond ETF CommonN/AN/AN/AN/AN/AN/AN/AN/AIPAImmunoPrecise Antibodies2.0421 of 5 stars3.53.00.00.01.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPMAptorum Group 0.00N/AN/AN/ACRDLCardiol Therapeutics 3.33Buy$8.00479.71% UpsideCXFCI Canadian Convertible Bond ETF Common 0.00N/AN/AN/AIPAImmunoPrecise Antibodies 3.00Buy$4.00143.90% UpsideCurrent Analyst Ratings BreakdownLatest CXF, CRDL, IPA, and APM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPMAptorum Group$430K17.05N/AN/A$2.20 per share0.62CRDLCardiol TherapeuticsN/AN/AN/AN/A$0.22 per shareN/ACXFCI Canadian Convertible Bond ETF CommonN/AN/AN/AN/AN/AN/AIPAImmunoPrecise Antibodies$17.59M4.30N/AN/A$0.93 per share1.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPMAptorum Group-$4.27MN/A0.00∞N/AN/AN/AN/AN/ACRDLCardiol Therapeutics-$26.77M-$0.34N/AN/AN/AN/A-209.63%-141.09%8/11/2025 (Estimated)CXFCI Canadian Convertible Bond ETF CommonN/AN/A0.00∞N/AN/AN/AN/AN/AIPAImmunoPrecise Antibodies-$20.13M-$0.68N/AN/AN/A-122.10%-40.62%-22.19%9/15/2025 (Estimated)Latest CXF, CRDL, IPA, and APM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025CRDLCardiol Therapeutics-$0.11N/AN/AN/AN/AN/A7/29/2025Q4 2025IPAImmunoPrecise Antibodies-$0.02-$0.04-$0.02-$0.04$7.89 million$5.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPMAptorum GroupN/AN/AN/AN/AN/ACRDLCardiol TherapeuticsN/AN/AN/AN/AN/ACXFCI Canadian Convertible Bond ETF CommonC$0.484.63%N/AN/AN/AIPAImmunoPrecise AntibodiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPMAptorum GroupN/A0.220.22CRDLCardiol Therapeutics0.013.263.26CXFCI Canadian Convertible Bond ETF CommonN/AN/AN/AIPAImmunoPrecise Antibodies0.492.082.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPMAptorum Group3.80%CRDLCardiol Therapeutics12.49%CXFCI Canadian Convertible Bond ETF CommonN/AIPAImmunoPrecise Antibodies6.70%Insider OwnershipCompanyInsider OwnershipAPMAptorum Group63.99%CRDLCardiol Therapeutics5.25%CXFCI Canadian Convertible Bond ETF CommonN/AIPAImmunoPrecise Antibodies6.83%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPMAptorum Group305.35 million1.93 millionNot OptionableCRDLCardiol Therapeutics2082.68 million78.31 millionNot OptionableCXFCI Canadian Convertible Bond ETF Common905.05 millionN/ANot OptionableIPAImmunoPrecise Antibodies8046.15 million43.00 millionNot OptionableCXF, CRDL, IPA, and APM HeadlinesRecent News About These CompaniesHC Wainwright Has Negative Outlook of IPA Q1 EarningsAugust 2 at 6:57 AM | marketbeat.comHC Wainwright Issues Negative Outlook for IPA EarningsAugust 2 at 3:41 AM | americanbankingnews.comImmunoPrecise Antibodies (NASDAQ:IPA) Issues Earnings ResultsJuly 30 at 9:18 AM | marketbeat.comIPA interactive stock chart | ImmunoPrecise Antibodies Ltd. stock - Yahoo FinanceJuly 29, 2025 | nz.finance.yahoo.comImmunoPrecise Antibodies Reports Record Revenue and GrowthJuly 29, 2025 | tipranks.comImmunoPrecise Antibodies Ltd. (IPA) Reports Q4 Loss, Lags Revenue EstimatesJuly 29, 2025 | zacks.comImmunoPrecise Antibodies Reports Record Fiscal Year 2025 ResultsJuly 29, 2025 | tipranks.comImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDAJuly 29, 2025 | businesswire.comImmunoPrecise Unveils Breakthrough in Predicting Drug Antibody RisksJuly 24, 2025 | tipranks.comImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the ClinicJuly 24, 2025 | businesswire.comImmunoPrecise Antibodies (IPA) Projected to Post Earnings on TuesdayJuly 22, 2025 | marketbeat.comImmunoPrecise Antibodies (NASDAQ:IPA) Shares Up 6% - Should You Buy?July 17, 2025 | marketbeat.comIPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025July 16, 2025 | businesswire.comImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price RequirementJuly 14, 2025 | financialpost.comFImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price RequirementJuly 14, 2025 | financialpost.comFImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price RequirementJuly 14, 2025 | businesswire.comImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors - MorningstarJuly 8, 2025 | morningstar.comMImmunoPrecise Antibodies Strengthens Board with Industry Veteran Jon LieberJuly 7, 2025 | tipranks.comImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training DataJuly 3, 2025 | businesswire.comImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® TechnologyJune 24, 2025 | businesswire.comWe're Keeping An Eye On ImmunoPrecise Antibodies' (NASDAQ:IPA) Cash Burn RateJune 18, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonHow a Government Loan Changes the Game for Plug PowerBy Jeffrey Neal Johnson | July 4, 2025View How a Government Loan Changes the Game for Plug PowerAmazon's Prime Day Pullback Meets Bullish Golden Cross SignalBy Gabriel Osorio-Mazilli | July 8, 2025View Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal3 Fast Food Stocks That Won’t Give You Indigestion Right NowBy Brian O'Connell | July 16, 2025View 3 Fast Food Stocks That Won’t Give You Indigestion Right NowCXF, CRDL, IPA, and APM Company DescriptionsAptorum Group NASDAQ:APM$1.37 -0.18 (-11.61%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.38 +0.01 (+0.66%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.Cardiol Therapeutics NASDAQ:CRDL$1.38 -0.11 (-7.38%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.40 +0.02 (+1.45%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.CI Canadian Convertible Bond ETF Common TSE:CXFC$10.36 -0.04 (-0.38%) As of 08/1/2025 01:18 PM EasternChimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.ImmunoPrecise Antibodies NASDAQ:IPA$1.64 -0.02 (-1.20%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.58 -0.05 (-3.35%) As of 08/1/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
